It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.

Dec 12 (Reuters) - GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory ...

According to DataM Intelligence, the Respiratory Syncytial Virus (RSV) Market Size reached USD 1.95 billion in 2024 and is projected to advance to USD 4.54 billion by 2033, expanding at a strong CAGR ...

Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...

Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 – $5.4 billion Increases 2025 expected year-end cash balance by $0.5 billion – $1 billion to a range of $6.5 – $7.0 ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 – $2.0 billion Improves 2025 expected GAAP operating ...

Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.15. In the year-ago period, the company had reported ...

The COVID-19 vaccine maker reported quarterly sales of $1.02 billion, topping the expected $886.54 million. Sales declined 45% to $1.9 billion from a year ago, primarily due to a $847 million, or 47%, ...

RSV vaccination for adults aged 60+ could prevent significant LRTD cases, hospitalizations, and deaths over five years. A 5-percentage-point increase in vaccine uptake could avert over 222,000 LRTD ...

Shares in Moderna and BioNTech have imploded since their 2021 peaks, shaving billions of dollars from their founders’ fortunes. Growing anti-vax hysteria and RFK Jr.’s FDA will likely make the ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Moderna, Inc. is placed among them. Moderna, Inc. (NASDAQ:MRNA), a Cambridge-based biotechnology leader, ...